Non-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice

Non-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice - Briumvi® - Real World Experience Study (BRILL Study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034406

Enrollment

700

Registered

2024-06-11

Start date

2024-06-14

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: RMS patients with active disease who are treated with newly prescribed Briumvi® (ublituximab) in routine clinical practice are enrolled after successful review of eligibility criteria and wr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Established clinical diagnosis of RMS with active disease. - Having been prescribed treatment with Briumvi® according to label and treatment is already initiated, with enrollment occurring no more than 90 days after the first dose. OR: Patient with newly prescribed Briumvi® in accordance with the label and about to start treatment with Briumvi® at Visit 1. - Ability to understand the purpose and risks of the study and willing to provide signed and dated study-specific ICF.

Exclusion criteria

Exclusion criteria: Patient cannot be regularly followed up for organizational or geographic reasons.

Design outcomes

Primary

Measure	Time frame
Treatment Satisfaction Questionnaire for Medication Version II (TSQM-II) score at Week 48 and Week 96 (or premature End-of-Study [EOS])	—

Secondary

Measure	Time frame
• Confirmation of treatment with Briumvi®: • Persistence to treatment: • Quality of life: • Clinical outcomes • Tolerability	—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactSilke Heeren

CLINVICES GmbH

silke.heeren@clinvices.com+49491773230861

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026